Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 21st International Conference on Clinical & Experimental Cardiology
(10 Plenary Forums - 1 Event) Las Vegas, USA.

Day 1 :

Keynote Forum

Richard A Schatz

Scripps Clinic, USA

Keynote: Cardiac applications of gene and stem cell therapy, update: 25 years and counting

Time : 10:40-11:20

OMICS International Cardiology 2017 International Conference Keynote Speaker Richard A Schatz photo

Richard A Schatz is best known for his role in developing the Palmaz-Schatz stent, the first balloon expandable stent used worldwide. His work started a revolution in interventional cardiology that continues today. Since 1998 he has participated in many gene and stem cell trials as a Principal Investigator. He continues to practice at Scripps Clinic in La Jolla, CA and lecture worldwide.


Despite over 25 years of intense research and development at great expense there has yet to be an approved gene or stem cell for cardiac applications. The earliest work began with using VEGF injected as a plasmid DNA directly into the myocardium by thoracotomy, then intra myocardially using a trans-aortic delivery mapping catheter for refractory angina. Others used VEGF/FGF genes or proteins injected intra coronary or intravenously. Despite encouraging phase I and II results, phase III trials were either abandoned or negative. This approach was soon replaced with using stem cells, first autologous then allogenic, for not only refractory angina but for refractory CHF and post MI remodeling. Again, despite encouraging phase I and II results no phase III trial has yet proven positive. This talk will discuss in detail these trials and why there has yet to be a positive trial. There is still controversy regarding the type of cells to use, the method of delivery, the dose and the proper patient subset to treat. Study design is important in order to standardize trials to make it easier to recruit and to win regulatory approval. Endpoints must be carefully chosen to assure a realistic outcome not just for FDA approval but for acceptance by the cardiology community. One of the more interesting lessons learned from these trials is the profound placebo effect that appears in all trial designs and outcomes. Trial design must account for this and power the studies appropriately. Currently there is only one FDA approved trial underway in the USA for refractory CHF and the results are pending. Stem cell therapy for refractory CHF, refractory angina and post MI remodeling represents a great opportunity yet has been unfulfilled thus far. Hopefully with lessons learned from past experience, improved products, delivery and study designs we will see a clinically useful indication for this difficult subset of patients without other options.

Keynote Forum

Robert Dumaine

Université de Sherbrooke, Canada

Keynote: Role of nicotine in cardiac arrhythmias leading to sudden infant death syndrome

Time : 10:00-10:40

OMICS International Cardiology 2017 International Conference Keynote Speaker Robert Dumaine photo

Robert Dumaine initiated and managed the Cardiac molecular genetic program at the Masonic Medical Research Laboratory (NY) from 1996-2004 and was Director of the department of Physiology and Biophysics at the University of Sherbrooke from 2004-2009. He is now full Professor at the department of Pharmacology and Physiology at the Univ. de Sherbrooke Qc. Canada. His expertise is on cardiac arrhythmias linked to potassium and sodium ion channel defects. His major contribution includes the discovery of arrhythmogenic mechanisms causing inherited and acquired forms of long QT syndrome, short QT syndrome and Brugada syndrome. In collaboration with P. Schwartz laboratory he published the first study linking SIDS to cardiac sodium channel defects. He pioneered research on the role of non-cardiac sodium channels in heart function and recently showed that overexpression of neuronal sodium channels in the heart could explain the QT prolongation and some of the arrhythmias observed in SUDEP and SIDS.


Goal of the Presentation: We will present evidence showing that in- utero exposure to nicotine creates a substrate for arrhythmias leading to sudden infant death syndrome (SIDS). Our goal is to raise awareness against the use of nicotine replacement therapies in pregnant women. 
Background: Sudden infant death syndrome (SIDS) is the leading cause of death in the first year of life. In-utero exposure to tobacco smoke is observed in 85% of SIDS cases and considered the highest risk factor. Therefore, nicotine replacement therapies are viewed as healthier alternatives to tobacco consumption and often prescribed to women who wish to quit smoking during pregnancy. However, of the 3000 toxic or carcinogenic compounds known to be present in tobacco smoke only tobacco glycoprotein (TGP) and nicotine were consistently linked to SIDS. While TGP triggers an anaphylactic response 3, only nicotine is associated to cardiac arrhythmias in newborns 4-10. Evidence linked SIDS to a failed coordination of the cardiovascular and respiratory systems during the postnatal development of the heart thus causing cardiac arrhythmias and sudden death 11-13. Among the hypothesis to explain SIDS is the failure of the newborn heart to accelerate at the onset of apnea and trigger awakening during sleep. In this talk we will present data showing that in-utero exposure to nicotine delayed the development of the heart conduction system and reduced the cardiac response to epinephrine. More specifically, our data show nicotine reduced the innervation of the sinoatrial node and the response of the cardiac sodium current responsible for triggering the ventricular action potential and exposure alters cardiac autonomic responsiveness: beta-adrenergic and m2-muscarinic receptors and their conduction of the electrical impulse within the heart.
Conclusion & Significance: Our results are consistent with the hypothesis that SIDS babies lack the cardio-respiratory reflex that accelerates the heart at the onset of apnea and may explain why some newborn infants do no awake during sleep apnea. The data provide a basis to explain the bradycardia and conduction anomalies observed in resuscitated SIDS infants and arrhythmias leading to crib death. Finally, our data raise awareness on the use of nicotine replacement therapies in pregnant women.

Break: Networking & Refreshment Break 11:20-11:40 @Foyer